for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Alliance Pharma plc

ALAPH.L

現在値

94.40GBp

変化

1.40(+1.51%)

出来高

2,213,434

本日のレンジ

92.10

 - 

94.90

52週レンジ

92.00

 - 

123.00

∙ 約20分前の相場を表示しています。

価格

前日終値
93.00
始値
93.00
出来高
2,213,434
3か月平均出来高
31.87
高値
94.90
安値
92.10
52週高値
123.00
52週安値
92.00
発行済株式数
539.79
時価総額
511.18
予想PER
14.31
配当利回り
1.79

次のエベント

Half Year 2022 Alliance Pharma PLC Earnings Release

適時開示

その他

Alliance Pharma Sees FY Financial Performance To Be In Line With Market Expectations

Alliance Pharma Chair David Cook To Step Down

Alliance Pharma FY PBT 18.2 Million Stg

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Alliance Pharma plcとは

Alliance Pharma plc is a United Kingdom-based holding company. The principal activity of the Company is the acquisition, marketing and distribution of consumer healthcare and pharmaceutical products. The Company's asset portfolio focused on two areas: Consumer Healthcare brands and Prescription Medicines. It holds marketing rights to approximately 80 consumer healthcare brands and Prescription Medicines, which are sold worldwide in approximately 100 countries. Its products include Aloclair, Alliance Calcium Syrup, Aiweidi, Biodermatin, Biotaches, Changmin, Decapional, Dermachronic, Dermacide, Dervida, Effadiane, Fazol, Flammacerium, Gen-Ongles, Irenat, Malunjunshe, MolluDab, Neostigmine and Nu-Seals and other. The Company’s brands also include Kelo-Cote, Nizoral, Amberen, MacuShield, Vamousse, Hydromol, Forceval, Ashton & Parsons, Anbesol, and Aloclair. Its geographical area includes Europe, Middle East and Africa (EMEA), Asia Pacific and China (APAC) and Americas (AMER).

業種

Biotechnology & Drugs

連絡先

Avonbridge House, Bath Road

SN15 2BB

United Kingdom

+44.1249.466966

https://www.alliancepharmaceuticals.com/

エグゼクティブリーダーシップ

David Cook

Independent Non-Executive Chairman of the Board

Peter Butterfield

Chief Executive Officer, Executive Director

Andrew Franklin

Chief Financial Officer, Executive Director

Stephen Kidner

Chief Scientific and Operations Officer

Janice Timberlake

Chief People and Infrastructure Officer

統計

1.40 mean rating - 5 analysts
Sell
Hold
Buy
Revenue (MM, GBP)

2019

0.1K

2020

0.1K

2021

0.2K

2022(E)

0.2K
EPS (GBp)

2019

4.990

2020

5.140

2021

6.300

2022(E)

6.446
株価売上高倍率(過去12カ月)
70.36
株価売上高倍率(過去12カ月)
3.13
株価純資産倍率(四半期)
1.80
株価キャッシュフロー倍率
29.34
総負債/総資本(四半期)
42.11
長期負債/資本(四半期)
41.94
投資利益率(過去12カ月)
1.55
自己資本利益率(過去12カ月)
1.45

最新ニュース

最新ニュース

米連邦地裁、薬価引き下げ巡るトランプ政権の新規則を一時差し止め

米メリーランド州の連邦地裁は23日、1月1日からの薬価引き下げに向けてトランプ政権が制定した規則の実施を差し止める仮処分決定を下した。

金融情報はリフィニティブから。すべての情報は少なくとも20分遅れで表示されています。

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up